TFA alludes to it: “They have created a lab-made alternative to test medicines, so no crabs are needed.
“It is the exact same protein, it is just made through biotechnology,” Bolden said.
Bolden said scientists at Eli Lilly tested thousands of samples on hundreds of different products and determined the alternative performs the same or better than purified horseshoe crab blood does.
Starting in 2016, Eli Lilly started to switch its testing to the lab-made version. Now 80 percent of it is done using the alternative.
The company plans to entirely eliminate the use of crab blood.”
Did not follow the industry since 2018, but it is quite a feat switching the supply chains to the recombinant version. Good to hear that they managed to do it. I wonder how other Pharma and Medtech players are doing in that regard.
But there are other options.
Here is a full disclaimer (from the trenches of startup land): I co-founded and ran a biotech startup that tried to disintermediate that particular supply chain. We even flew to SF to speak to some of the YC chaps, and talked to a strategic buyer. Our technology R&D failed to deliver, unfortunately. And the market is fairly small. But I learned a great deal re that particular business, and a lot of more general lessons. All in all, a crazy run with so many crazy stories, I need to write them down one day.
Horseshoe crabs are truly fascinating animals in respect to their physique, lineage and behaviour. But these things one can read up on Wikipedia.
We had quite a bunch of them in our lab (and living room). They were supposed to be voracious predators to all things they can eat, but ours developed a rather expensive habit in captivity by only eating the most expensive of goods from the local fish market. They would not eat anything else.